Cancer drugs known as BET inhibitors once looked like a breakthrough, but in real patients they\u2019ve often fallen short. New research reveals a key reason why: two closely related proteins, BRD2 and BRD4, don\u2019t actually do the same job. Instead, BRD2 acts like a \u201cstage manager,\u201d preparing genes for activation, while BRD4 triggers the final step that turns them on. By blocking both at once, current drugs may be disrupting the process in unpredictable ways.<\/p>\n","protected":false},"excerpt":{"rendered":"
Cancer drugs known as BET inhibitors once looked like a breakthrough, but in real patients they\u2019ve often fallen short. New research reveals a key reason…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-784","post","type-post","status-publish","format-standard","hentry","category-blog"],"yoast_head":"\n